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ORIGINAL ARTICLE

Bayesian Model Averaging with Change Points to Assess
the Impact of Vaccination and Public Health Interventions
Esra Kürüm,a Joshua L. Warren,b Cynthia Schuck-Paim,c Roger Lustig,c Joseph A. Lewnard,d
Rodrigo Fuentes,e Christian A. W. Bruhn,d Robert J. Taylor,c Lone Simonsen,c,f and Daniel M. Weinberger d
Background: Pneumococcal conjugate vaccines (PCVs) prevent
invasive pneumococcal disease and pneumonia. However, some lowand middle-income countries have yet to introduce PCV into their
immunization programs due, in part, to lack of certainty about the
potential impact. Assessing PCV benefits is challenging because specific data on pneumococcal disease are often lacking, and it can be
difficult to separate the effects of factors other than the vaccine that
could also affect pneumococcal disease rates.
Methods: We assess PCV impact by combining Bayesian model averaging with change-point models to estimate the timing and magnitude
of vaccine-associated changes, while controlling for seasonality and
other covariates. We applied our approach to monthly time series of
age-stratified hospitalizations related to pneumococcal infection in children younger 5 years of age in the United States, Brazil, and Chile.
Results: Our method accurately detected changes in data in which we
knew true and noteworthy changes occurred, i.e., in simulated data
and for invasive pneumococcal disease. Moreover, 24 months after
the vaccine introduction, we detected reductions of 14%, 9%, and 9%
in the United States, Brazil, and Chile, respectively, in all-cause pneumonia (ACP) hospitalizations for age group 0 to <1 years of age.
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Conclusions: Our approach provides a flexible and sensitive method
to detect changes in disease incidence that occur after the introduction of a vaccine or other intervention, while avoiding biases that
exist in current approaches to time-trend analyses.
(Epidemiology 2017;28: 889–897)

P

neumococcus (Streptococcus pneumoniae) causes an array
of diseases, including pneumonia and invasive pneumococcal disease (IPD), resulting in almost 1 million childhood
deaths annually in the pre-vaccine years.1 The first pneumococcal conjugate vaccine (PCV7), which targeted seven of the 90+
pneumococcal serotypes, was introduced in 2000 in the United
States. Newer versions of the vaccine on the market, PCV10 and
PCV13, target 10 and 13 serotypes, respectively, are now in widespread use worldwide. Accurate determination of PCV impact is
necessary to support public health decision-making. In particular,
many low- and middle-income countries are considering introducing or have already introduced PCVs. These countries will
need information about the overall impact of PCVs as they decide
whether to implement or continue to support PCVs in the future.
The ability to detect a vaccine-associated change in disease rates depends on the magnitude of the decline and the
amount of unexplained variability in the data—a small change
in noisy data is difficult to see. Analysis of bacterial surveillance
data,2,3 as well as trends in national mortality,4 and hospitalization data5 have shown that the use of PCVs led to substantial
declines in rates of IPD among both vaccinated children and
unvaccinated older children and adults. Estimating the impact
of PCVs on IPD is relatively straightforward because the decline
is large and corroborated by laboratory testing. However, measuring the impact of PCVs against pneumonia is more difficult
because the etiologic agent is rarely identified or recorded. Randomized controlled trials (RCTs) suggest that PCVs should have
a relatively modest effect of 0.1%–10.8% against syndromic
pneumonia hospitalizations among children <2 years of age.1 In
contrast, some time-trend studies have reported declines of up
to 40% in all-cause pneumonia hospitalizations.6,7 However, in
observational studies of this type, changes in healthcare systems
and socioeconomic improvements are all nonvaccine factors
that may influence reported reductions, as could the specificity
www.epidem.com | 889
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of the pneumonia case definitions. Robust methods that quantify
the timing and magnitude of any changes that occur after vaccine introduction would help to strengthen estimates of vaccine
impact and improve comparability between studies.
A common approach used to estimate vaccine impact is
interrupted time series analysis, which involves using a regression
model to evaluate changes in incidences or trends between selected
pre- and post-vaccine years. This approach, however, requires two
potentially problematic assumptions. First, it prespecifies the point
in time when a change in the outcome is expected (typically at or
shortly after vaccine introduction). This is problematic because it
is uncertain when a vaccine will begin to exert a detectable effect,
and the estimated reductions can depend greatly on the choice of
the cut-off point. Also, if an unrelated trend begins shortly before
vaccine introduction, this change could be incorrectly attributed
to the vaccine. And a short-term spike in incidences that occurs
shortly before vaccine introduction—such as the 2009 pandemic
occurring just before PCV10 introduction in Brazil and PCV13
in the United States in 2010—could influence the estimated prevaccine trends and bias the results. These sources of bias are usually not well investigated. Second, investigators typically choose
one model over all others, when in fact alternative models might
describe the data equally well but nonetheless may yield different
impact estimates.8 For example, a model that assumes an immediate, sudden decline in incidences due to vaccine might give biased
results if, in fact, the decline is delayed or gradual. In practice,
investigators do not know the structure of changes in incidence or
which nonvaccine forces may be operating. Therefore, assuming
that one model can describe the data adequately is not optimal.
To address these issues, we have combined change-point
analysis9—a method to detect the timing and magnitude of changes
in time series data—with Bayesian model averaging—a method to
systematically integrate results from different model structures and
covariates. Change-point modeling allows the data to reveal if and
when any substantial change in the time series occurred, with fewer
presuppositions. Bayesian model averaging obviates the need to
choose a single “best” model by providing a weighted average
of results from models fitted using different forms and combinations of covariates; it also provides insight into the importance of
each covariate included in the change-point models. This approach
allows assessment of the uncertainties in timing and magnitude of
any changes found in the time series. Here, we demonstrate the
usefulness—and limitations—of this approach by applying it to the
assessment of PCV impact in the United States, Brazil, and Chile.
We also provide the results of a Monte Carlo simulation study that
assessed the accuracy and precision of our approach.

METHODS
Data Sources
We obtained monthly hospitalization data from three countries: the United States, Brazil, and Chile. We focused our study
on children <5 years of age (stratified by <12, 12–23, and 24–59
months of age) because pediatric age groups are most likely to be
directly affected by vaccination. PCV7 was introduced in the United
890 | www.epidem.com

States in February 2000, and PCV10 was introduced in Brazil and
Chile in March 2010 and January 2011, respectively. See eAppendix (http://links.lww.com/EDE/B237) for details on data sources.
In the US data, we used any mention of the relevant International classification of diseases, ninth revision (ICD9) codes
(eTable 1; http://links.lww.com/EDE/B237) in the hospitalization discharge records to define patients who had IPD and pneumococcal (lobar) pneumonia; for all-cause pneumonia, we used
two definitions: the ICD9 definition that Griffin et al10 (2013)
developed, and a less stringent but commonly used “any mention” definition (referred here as the “standard definition”). In
Brazil and Chile, codes specifically indicating pneumococcal
pneumonia and pneumococcal infection were rarely used, and
secondary codes were not recorded; thus, we could only analyze
ACP defined by the “standard” definition (eTable 1; http://links.
lww.com/EDE/B237). To highlight the strengths and pitfalls of
our approach, we also present results of the model fit to rotaviral
enteritis and urinary tract infections (UTIs) for which no PCV
benefits are expected. The analyses of these de-identified data
were deemed exempt from review by the Human Investigation
Committee at Yale School of Medicine.

Bayesian Model Averaging with Change Points:
Overview
We combined change-point models with Bayesian model
averaging. We fit two types of change-point models11–13: one capturing sudden declines (change in mean) and the other capturing
gradual declines over time (change in slope). To allow for the possibility that no significant change occurred, we also fit models with
no change point. To capture time trends not explained by the change
points, all models included a smooth function of time, which was
estimated using a nonparametric mixed model approach, and therefore lead to inclusion of random effects (for details, see eAppendix;
http://links.lww.com/EDE/B237). We also allow a set of covariates
to be included in the model, and the outcome Y j is assumed to follow a Poisson distribution with mean µ j .
The three model structures were as follows:
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and β = β1 , β2 ,…, β p are the vectors of covariates and p regression coefficients, respectively,
α is the coefficient of change point, i.e., the change in
X j = X 1 j , X 2 j ,…, X pj
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expected counts due to the intervention that occurs at time θ ,
and I u is an indicator function that is 1 when its subscript is
greater than 0 and is 0 otherwise, and j=1,2,…,n with n as the
number of time points.
For Bayesian model averaging, we fit each of the three
model structures with all possible combinations of covariates
and each candidate change point. This resulted in a large set of
candidate models. For details of the estimation procedure, see
eAppendix (http://links.lww.com/EDE/B237).
We placed two restrictions on our models. First, to minimize edge effects, which are typical in the analyses of time
series data and can lead to biased results, we assumed the
probability that a change point occurred in the first or last 6
months of the time series was 0. Second, in data applications
where more than one change point was needed to capture the
variation in the data, we required each point be separated by at
least 12 months from all others, to avoid capturing short-term
epidemic patterns.

Estimating the Counterfactual Predictions
To estimate the decline in incidences that occurred after
vaccine introduction, it is necessary to compare the modelaveraged fitted incidences with an estimate of the counterfactual incidence (counterfactual prediction)—what would have
been expected to occur if the vaccine was not introduced. We
estimated the counterfactual incidence by using the model that
was fit to the entire data.
While estimating the counterfactual predictions, there are
three possible scenarios to consider: (1) no change in incidence;
(2) change in incidence before the vaccine; and (3) change in
incidence after the vaccine. If there were no changes or a change
occurred before the vaccine, no change should be attributable
to the vaccine, and the counterfactual predictions should align
with model-averaged fitted values. In contrast, if the change
occurred after vaccine introduction, this change should be
attributed to the vaccine. To implement this idea in our models,
we multiplied the regression coefficients of the change points
(α in equations 2 and 3) by the sum of the posterior probabilities
from the models that indicated a change occurred before the
vaccine or no change at all. If the models with a change point
before the vaccine fit the data better, we multiply α (equations
2 and 3) with a number close to 1 and the counterfactual predictions will be close to model-averaged fitted values. On the
contrary, if the models with a change point after the vaccine
fit the data better, we multiply α with a number close to 0, and
the counterfactual predictions will be further away from modelaveraged fitted values.
We obtained the incidence rate ratio (IRR)—a measure
of the magnitude of the change for each time point—by dividing model-averaged fitted values by counterfactual predictions.
We obtained 95% bootstrap confidence intervals for the IRR
(for details, see eAppendix; http://links.lww.com/EDE/B237).
We assessed the uncertainty associated with the existence and location of each change point using the distribution
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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of posterior probabilities. The sum of the posterior probabilities for the models with a change point gives an indication of
the confidence that there was a substantial change in the time
series data—posteriors close to 1 indicates strong evidence
of a change, values close to 0 indicate strong evidence of no
change, and values close to 0.5 indicate uncertainty about
whether there was a change.

Bayesian Model Averaging with Change Points:
Applications
National-level Hospitalizations
We applied Bayesian model averaging with change
points to the national-level hospitalization data from the
United States, Chile, and Brazil. All analyses were stratified
by age group, and separate models were fit for each disease
outcome (eTable 1; http://links.lww.com/EDE/B237). In each
analysis, the total number of hospitalizations in the relevant age
group and year, excluding the hospitalizations for the outcome
of interest, was used as the denominator. As a starting point
for all of the analyses, we allowed a single change point at an
unknown time. Because the resulting posterior model probabilities suggested that we needed two change points, i.e., we had
a bimodal posterior distribution, to explain the patterns in the
United States and Chile, we reanalyzed these data allowing up
to two change points that were separated by at least 12 months.
In Brazil, a health program (Pact for Health) targeting diarrhea
and pneumonia began in 2006, and a 2008 healthcare delivery
system reform affected the specificity of coding; thus, for Brazil, we included two fixed change points in January 2006 and
2008 (a dummy variable for before or after that time point) and
allowed a single change point any time after January 2009. In
the analysis of pneumonia and invasive pneumococcal disease,
all models included harmonic terms with 6- and 12-month periods to capture the seasonal structure of the data. In addition, we
included age-adjusted numbers of influenza hospitalizations as
a covariate to control for the severity of different influenza seasons; numbers of influenza cases were aggregated over all age
groups to provide an estimate of influenza activity across the
population and avoid known age-specific coding biases.

Simulation Studies
We generated five sets of simulated time series that
resembled observed time series in terms of number of monthly
cases, seasonality, and degree of random unexplained variability but on which we imposed changes of known timing and
magnitude. For each set, we generated 100 time series that followed a Poisson distribution, and parameters for this distribution were extracted from invasive pneumococcal disease and
pneumonia time series from the United States, Chile, and Brazil using a Poisson regression model in PROC MCMC (SAS
Inc., Cary, NC).14 The last simulation study used parameters
obtained from Brazil pneumonia series and was used to demonstrate the performance of Bayesian model averaging with
change points in the absence of a vaccine effect. For details
www.epidem.com | 891
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on construction of simulated data, see eAppendix (http://links.
lww.com/EDE/B237).
We evaluated the performance of the proposed models
first in terms of IRR estimations by comparing the median
estimated IRR of all 100 simulated data sets to the true IRR
value at 12 months after the change point. At the same time
point, we also assessed the uncertainty associated with IRR
estimation through coverage of the 2.5 and 97.5 percentiles
of estimated IRR values based on 100 simulation runs. We
assessed the precision of our change-point estimates by comparing the true change-point locations to mean change-point
locations, which were calculated as the average of the time
points in each simulation run that had the largest posterior
probability.
We compared the performance of Bayesian model averaging with change points in estimating IRR to interrupted time
series approach in simulated data and real data applications.
See eAppendix (http://links.lww.com/EDE/B237) for details.
Bayesian model averaging with change points was performed using the GAMM4 package in R V3.1.3 (R, Vienna,
Austria),15 and a sample R code (http://links.lww.com/EDE/
B238) along with a data set (http://links.lww.com/EDE/B239)
is available as supplementary materials.

RESULTS
Performance of Models on Simulated Time
Series
We applied Bayesian model averaging with change
points to five sets of 100 simulated time series, which had
different effect sizes and number of years observed (eTable
2; http://links.lww.com/EDE/B237). The method accurately
detected the timing and magnitude of changes when vaccine
effect was large (similar to the ~60% reduction seen in invasive pneumococcal disease in the United States3) (eFigure
1; http://links.lww.com/EDE/B237). The model accurately
captured both the timing of the change and the magnitude of
the decline after the simulated vaccine introduction. In the
simulated data where there was no imposed vaccine effect,
Bayesian model averaging with change points—correctly—
did not detect a change in 69% of the simulated time series.
The method performed well when estimating the change-point
location(s) in simulated data where the imposed decline was
smaller and several years of data before and after vaccine were
available (the data were similar to ACP [definition in 10] in
the United States and Brazil). However, when only 2 years of
post-vaccine data were available, as was the case with simulated data that resembled all-cause pneumonia in Chile, IRR
estimates were slightly biased. Finally, when the expected IRR
was small, change-point estimate was less accurate, with up to
a year between this estimate and true change point.
The comparison of Bayesian model averaging with
change points with interrupted time series analysis (eTable 3;
http://links.lww.com/EDE/B237) showed that for data with a
892 | www.epidem.com

single change point (similar to characteristics of Brazil allcause pneumonia data), these methods gave mostly comparable results. With two change points, the results of interrupted
time series analysis and Bayesian model averaging with
change points were closest when the cut-off for interrupted
time series was close to the mean second change point calculated with Bayesian model averaging with change points
(eTable 2; http://links.lww.com/EDE/B237) (for details, see
eAppendix; http://links.lww.com/EDE/B237).

Estimates of Changes Following the
Introduction of PCVs
Within 24 months of vaccine introduction, large
declines (36%–43%) had occurred in rates of invasive pneumococcal disease in the United States among children under
5 years of age. For invasive pneumococcal disease, the probability that at least one change point occurred after vaccine
introduction was strong (probability of 0.999 for age groups
<12-, 12–23-, and 24–59-month-olds). The posterior probabilities indicated that a second change point occurred 4–7
years after vaccine introduction as disease rates leveled out
(Figure 1 and Table). By 24 months after PCV7 introduction,
pneumococcal (lobar) pneumonia declined by 36%, 43%, and
32% among children <12, 12–23, and 24–59 months of age
in the United States, respectively. The corresponding probabilities that a change occurred after PCV7 introduction were
0.977, 0.999, and 0.999 (eFigure 2; http://links.lww.com/
EDE/B237; Table).
All-cause pneumonia declined by 14%, 9%, and 9%
among <12-month-olds in the United States, Brazil, and Chile,
respectively, at 24 months after PCV introduction. The probabilities that a decline occurred after PCV introduction were
0.956, 0.498, and 0.998 in the United States, Brazil, and Chile,
respectively. For older children, the probability of a decline
after PCV introduction was in all three countries greater than
0.8. Using a definition of ACP that is more specific for pneumococcus,10 the decline in the Unites States was, as expected,
larger at 26% (Figure 2; eFigures 3–6; http://links.lww.com/
EDE/B237; Table).
Our method can make use of covariates to control for
changes that are unrelated to vaccination. For example, for
the stringent all-cause pneumonia definition10 in the United
States, there was weak evidence that influenza (eTable 1;
http://links.lww.com/EDE/B237) should be included in the
model for <12-month-olds (probability = 0.389), while there
was strong evidence (probability = 0.891) that it should be
included in models for 24–59-month-olds (Table).
We compared the results of Bayesian model averaging with change points to an interrupted time series model
(eTable 4; http://links.lww.com/EDE/B237). The estimates for
the decline in pneumonia hospitalizations after PCV introduction obtained from the former method were generally closer to
zero (i.e., smaller effects) (for details, see eAppendix; http://
links.lww.com/EDE/B237).
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 1. The plots on the left represent, IPD hospitalizations versus time for 10 US states by age group, showing observed IPD
hospitalizations per month (black), model-averaged fitted values (orange, solid) with their 95% approximate pointwise confidence intervals (orange, dotted), and counterfactual predicted values (blue). The estimated decline at specific time points (green
triangles) is shown, with their respective 95% bootstrap confidence intervals. The blue dots at the bottom represent the probability of a change occurring at that point. The color gets darker as the probability increases. The first and second sets of dots are
for the first and second change points, respectively. The level plots on the right are posterior probabilities corresponding to the
plots on the left for the locations of the first (x axis) and second (y axis) change points. The dashed lines represent the time that
the PCV7 (January 2000) is introduced.
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE. Estimated Percent Decline ([1-IRR] × 100) and Probabilities that Changes Occurred After Vaccination by Age Group,
Country, and Outcome
Percent Decline 24
Months After Vaccine
Introduction (95%
CI), %

Outcome/Age Group

Invasive pneumococcal disease (United States)
 0 to <12
 12–23
 24–59
Pneumococcal (lobar) pneumonia (United States)
 0 to <12
 12–23
 24–59
All-cause pneumonia
 0 to <12 (US definition by Griffin et al10)
 0 to <12 (US standard definition)
 0 to <12 (Brazil)
 0 to <12 (Chile)
 12–23 (US definition by Griffin et al10)
 12–23 (US standard definition)
 12–23 (Brazil)
 12–23 (Chile)
 24–59 (US definition by Griffin et al10)
 24–59 US standard definition)
 24–59 (Brazil)
 24–59 (Chile)

Percent Decline 48
Months After Vaccine
Introduction (95%
CI), %

Probability of Any
Change in the Time
Series

Probability of Any
Change Occurring
After Vaccine
Introductiona

Probability
that Influenza
Influences
Estimates

43 (26, 51)
77 (52, 78)
36 (20, 42)

64 (42, 66)
76 (58, 81)
61 (40, 65)

1.000
1.000
1.000

0.999
0.999
0.999

0.638
0.623
0.439

36 (21, 38)
43 (25, 47)
32 (21, 42)

37 (21, 40)
44 (26, 45)
28 (7, 32)

1.000
1.000
1.000

0.977
0.999
0.999

0.640
0.736
0.720

26 (10, 28)
14 (8, 22)
9 (3, 14)
9 (1, 17)
10 (2, 12)
5 (1, 7)
6 (1, 9)
18 (4, 26)
−3 (−5, 1)
−2 (−3, 1)
9 (3, 11)
5 (−1, 6)

33 (11, 34)
19 (9, 24)
10 (4, 19)
—
10 (2, 12)
6 (1, 7)
7 (1, 10)
—
−3 (−6, 1)
−4 (−5, −1)
11 (4, 13)
—

1.000
1.000
1.000
1.000
0.999
0.933
0.816
0.815
0.999
0.999
0.999
0.392

0.994
0.956
0.498
0.998
0.995
0.933
0.941
0.915
0.998
0.998
0.923
0.885

0.389
0.650
0.559
0.153
0.760
0.774
0.165
0.415
0.891
0.678
0.814
0.224

a
Probability conditional on there being any change.
CI indicates confidence interval.

Estimates of Changes in Nonpneumococcal
Outcomes
In the United States, Bayesian model averaging with
change points did not detect a decline in rotaviral enteritis immediately after PCV introduction (as expected) but
detected a decline in <12-month-olds after 2006, coincident with the introduction of the rotavirus vaccine. We also
detected a decline in the number of UTI cases in the United
States after 2000 among infants <12 months of age and among
children 12–23 months of age. In Brazil, we did not detect
any changes in UTI cases in infants <12 months of age after
PCV introduction (eFigure 7 and eTable 5; http://links.lww.
com/EDE/B237). These patterns highlight the need for caution when attributing trends from these types of analyses to a
specific intervention.

DISCUSSION
The benefits of a public health intervention are typically
assessed from time series data using a regression model that
compares disease rates and trends before and after the intervention. The advantage of Bayesian model averaging with
change points over this traditional approach is two-fold. First,
it estimates the time at which a change in incidence occurred
rather than imposing a preselected time frame on the analysis,
894 | www.epidem.com

making it less likely that an unrelated trend from before vaccine introduction would be attributed to the vaccine. Second,
it removes the need to choose a single “best” model structure to describe the data. In practice, analysts might not know
the structure of change(s) in incidences or the covariates that
describe the data best. We avoid this limitation by fitting a
number of possible models with different combinations of
covariates.
We have demonstrated the advantages of Bayesian
model averaging with change points by assessing PCV impact
in three different epidemiologically distinct settings. Two of
these were middle-income countries for which we only had
data on all-cause pneumonia, the pneumococcal outcome that
is least specific and therefore most challenging to assess. We
believe that this method could be used effectively to evaluate
the impact of other vaccines and public health interventions in
many such settings, including low-income countries in which
the data are even more challenging.
Comparison of Bayesian model averaging with changes
points and interrupted time series analysis indicates that both
methods yield similar results when there is a single change
point in the data and the latter correctly specifies this point as
the cut-off. In practice, however, the exact point to interrupt
the time series may not be optimal. Our results show that if the
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 2. The plots on the right are ACP hospitalizations versus time for Brazil (first row), 10 US states (second row), and Chile
(third row) for age group 0–12 months, showing observed ACP hospitalizations per month (black), model-averaged fitted values
(orange, solid) with their 95% approximate pointwise confidence intervals (orange, dotted), and counterfactual predicted values
(blue). The estimated decline at specific time points (green triangles) is shown, with their respective 95% bootstrap confidence
intervals. The blue dots at the bottom represent the probability of a change occurring at that point. The color gets darker as the
probability increases. In the second and third rows of the plot, the first and second sets of dots are for the first and second change
points, respectively. The level plots on the right are posterior probabilities (in the second and third rows) corresponding to the
plots on the left (in the second and third rows) for the locations of the first (x axis) and second (y axis) change points. The dashed
lines represent the time that the pneumococcal conjugate vaccine is introduced.

data are not interrupted at the correct time point, the estimate
of interrupted time series will be biased. Moreover, it tends to
estimate larger percent declines for data with more than one
© 2017 Wolters Kluwer Health, Inc. All rights reserved.

change point (eTable 3; http://links.lww.com/EDE/B237). For
analysts who decided to perform interrupted time series as the
primary analysis and where there is strong prior information
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about when the change should occur, we would suggest that
Bayesian model averaging with change points would provide
a useful secondary analysis with an additional confirmatory
information (the timing of the change).
Because contact patterns between age groups are not
uniform, and the etiology of pneumonia varies by age, the
change-point locations and magnitudes could differ by age
group. Therefore, we performed a separate analysis for each
age group and disease outcome. Our analysis supported this
approach as the declines in some disease outcomes are earlier in vaccinated children compared with unvaccinated adults
(who are indirectly protected).
The estimated decline in invasive pneumococcal disease in children under 24 months of age was consistent with
results from active surveillance studies; pneumococcal (lobar)
pneumonia in the United States, an outcome that is more specific for pneumococcal pneumonia than all-cause pneumonia,
declined in a similar pattern after PCV introduction. However,
our estimates of the decline in all-cause pneumonia (standard
definition) among children <24 months of age were notably
smaller than some published estimates from trend studies. For
example, Afonso et al7 (2013) estimated a 24%–29% decline
in Brazil, and Grijalva et al6 (2007) found a 39% decline in
all-cause pneumonia (stringent definition) in the Unites States.
Some of the differences between our results and published
studies could be due to differences in the definition of pneumonia used; in fact, we detected a larger decline (26%) when
using the stringent all-cause pneumonia definition,10 suggesting that this definition is more specific to pneumococcus than
the standard definition. Our estimates, however, are more consistent with the declines in clinical pneumonia estimated in
RCTs.1 Importantly, when there is uncertainty about whether
a trend begins before or after vaccine, Bayesian model averaging with change points is inherently more conservative in estimating the amount of change that occurred after vaccine than
interrupted time series or other similar methods. Comparisons
with these other methods can be helpful to highlight situations
where the simpler interrupted time series approaches might be
biased and further analytical attention is needed.
Covariates can be incorporated into Bayesian model
averaging with change points to control for changes in incidence unrelated to vaccination. As an example, we included
age-aggregated influenza hospitalizations (ICD10 J09–J11) as
a covariate to control for the highly variable severity of seasonal
influenza because a severe influenza season could bias IRR and
change-point estimates for pneumonia (and potentially hospitalizations caused by pneumococcus specifically as well).16,17
For instance, a severe flu season immediately after vaccine
would lead to an increase in pneumonia hospitalizations and
mask the effect of the vaccine, while a severe season before vaccine would exaggerate the effect. The influenza covariate allows
us to subtract out the effect of influenza from the estimates.
Although including this covariate might bias the estimates if
the vaccine reduces hospitalizations coded as influenza or if
896 | www.epidem.com

coding patterns changed after vaccine, it is still important to
control for influenza season severity for the reasons mentioned
above. By summing the weights of models that include influenza, we obtained an estimate of the probability that influenza
appreciably influenced the results; values close to 1 were strong
evidence that it did, values near 0 were strong evidence that it
did not, and values near 0.5 were inconclusive (Table).
Our approach has limitations. First, Bayesian model
averaging with changes points requires an investigator to
determine the number of change points before fitting the
models; we are developing a more flexible approach that will
estimate the appropriate number of change points. Second, its
algorithm is computationally heavy due to the smooth functions of time used in the models. Therefore, fully Bayesian
approaches that employ spike-and-slab priors will be explored
to overcome this burden. Third, more simulation studies are
required to determine the effects of sample size, unexplained
variability, and effect size on the accuracy of the estimates.
Finally, an inherent limitation of both Bayesian model averaging with change points and interrupted time series is the need
to assume that any trends that occurred before vaccine would
continue indefinitely into the post-vaccine period. Incorporating information on contemporaneous control variables into
the analysis18 could help to relax these assumptions and generate more credible counterfactual estimates.
As with any trend analysis, the results of Bayesian
model averaging with change points should be interpreted
cautiously. Although it strengthens inferences on vaccine
impact by estimating the timing and magnitude of the change
after the intervention, unrelated factors can still influence
trends in incidences. For instance, we found changes in UTI
hospitalizations in the United States (but not in Brazil) after
PCV introduction that cannot plausibly be attributed to PCV.
One solution to this problem would be to identify an appropriate set of comparison outcomes that share the same set of
confounders as the disease of interest but is not influenced by
the intervention.19 Identifying these outcomes is challenging
in practice, as using an inappropriate outcome might lead to a
misleading association between the vaccine and the comparator outcome. We chose UTI and rotaviral enteritis to demonstrate the challenge in selecting such outcomes and to reiterate
that caution should be exercised when attributing any change
found in pneumonia-related hospitalizations to the vaccine.
In conclusion, we have proposed a flexible approach
to evaluate the impact of PCVs, as well as any public health
intervention. Our approach estimates the location and magnitude of the change in disease incidence by fitting a number of alternative models that account for different potential
covariates and different structures of the change. Unlike current approaches, our method removes the need to subjectively
select the change point in the time series and calculate the
intervention impact accordingly. The utility of our approach is
demonstrated via simulation studies and real data with strong
and known vaccine effects.
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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